Kestra Medical Technologies (KMTS) Cost of Revenue (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Cost of Revenue data on file, last reported at $11.6 million in Q1 2026.

• Quarterly Cost of Revenue rose 36.32% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $42.9 million (up 23.79% YoY) and the FY2025 annual result came in at $35.6 million, up 29.7% from the prior year.
• Cost of Revenue climbed to $11.6 million in Q1 2026 per KMTS's latest filing, from $11.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $11.6 million in Q1 2026 and bottomed at $7.4 million in Q1 2024.
• The 3-year median for Cost of Revenue is $8.9 million (2024), against an average of $9.4 million.
• The widest annual swing landed in 2025, when Cost of Revenue climbed 10.89%; it then surged 36.32% in 2026.
• Tracing KMTS's Cost of Revenue over 3 years: stood at $8.9 million in 2024, then gained by 25.46% to $11.1 million in 2025, then climbed by 4.53% to $11.6 million in 2026.
• Per Business Quant, the three latest KMTS Cost of Revenue figures stand at $11.6 million (Q1 2026), $11.1 million (Q4 2025), and $10.5 million (Q3 2025).

Peer Comparison